Citadel Advisors
DFTX

Citadel Advisors’s Definium Therapeutics DFTX Stock Holding History

Citadel Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.62M Sell
85,700
-155,200
-64% -$2.63M ﹤0.01% 6558
2025
Q4 		$3.23M Buy
240,900
+130,600
+118% +$1.62M ﹤0.01% 5040
2025
Q3 		$1.3M Buy
110,300
+42,500
+63% +$396K ﹤0.01% 6974
2025
Q2 		$440K Sell
67,800
-34,300
-34% -$226K ﹤0.01% 8937
2025
Q1 		$597K Sell
102,100
-66,500
-39% -$476K ﹤0.01% 8090
2024
Q4 		$1.17M Buy
168,600
+51,100
+43% +$352K ﹤0.01% 6694
2024
Q3 		$669K Buy
117,500
+3,200
+3% +$22.3K ﹤0.01% 7650
2024
Q2 		$824K Sell
114,300
-139,000
-55% -$1.22M ﹤0.01% 6995
2024
Q1 		$2.38M Buy
253,300
+133,584
+112% +$762K ﹤0.01% 5188
2023
Q4 		$438K Buy
119,716
+54,000
+82% +$163K ﹤0.01% 8387
2023
Q3 		$206K Sell
65,716
-37,000
-36% -$152K ﹤0.01% 9852
2023
Q2 		$367K Sell
102,716
-23,900
-19% -$82.4K ﹤0.01% 8597
2023
Q1 		$401K Sell
126,616
-161,270
-56% -$536K ﹤0.01% 8765
2022
Q4 		$633K Buy
287,886
+9,528
+3% +$26.5K ﹤0.01% 7760
2022
Q3 		$974K Buy
278,358
+257,211
+1,216% +$2.47M ﹤0.01% 7050
2022
Q2 		$203K Buy
21,147
+627
+3% +$7.93K ﹤0.01% 10661
2022
Q1 		$342K Buy
20,520
+5,300
+35% +$92K ﹤0.01% 10294
2021
Q4 		$315K Sell
15,220
-2,867
-16% -$91.5K ﹤0.01% 10824
2021
Q3 		$632K Buy
18,087
+1,480
+9% +$64K ﹤0.01% 9304
2021
Q2 		$859K Buy
+16,607
New +$872K ﹤0.01% 8749

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors's DFTX Position: Q1 2026 in Review

Citadel Advisors increased its Definium Therapeutics (DFTX) stake by 535% in Q1 2026, buying an estimated $19.1M and bringing the position to 1,333,442 shares worth $25.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2051.

Citadel Advisors first reported a position in DFTX in Q2 2021 and has held it in 19 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Citadel Advisors held 1,333,442 shares of Definium Therapeutics worth $25.2M as of Q1 2026.
  • Citadel Advisors bought 1,123,498 Definium Therapeutics shares in Q1 2026, an estimated $19.1M.
  • Definium Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2051 holding.
  • Citadel Advisors first reported a position in Definium Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.